Self-reported musculoskeletal disorders and associated factors among HIV/AIDS patients following ART at University of Gondar Comprehensive Specialized Hospital, Gondar, Ethiopia, 2021: Aa cross-sectional study design.
Anti-retroviral medication
Ethiopia
HIV/AIDS patients
Musculoskeletal disorder
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
18 Aug 2023
18 Aug 2023
Historique:
received:
15
12
2022
accepted:
31
07
2023
medline:
21
8
2023
pubmed:
19
8
2023
entrez:
18
8
2023
Statut:
epublish
Résumé
Musculoskeletal disorders is an inflammatory, degenerative diseases and disorders that cause pain and functional impairments. Musculoskeletal disorders are common and the major global health concern among people with human immunodeficiency virus/acquired immunodeficiency syndrome which causes physical disability. Despite, it is a recognized health problem among human immunodeficiency virus-positive patients, there is a lack of data on musculoskeletal disorders among patients following anti-retroviral therapy in sub-Saharan Africa, particularly Ethiopia. Therefore, the main aim of the study was to assess the prevalence and associated factors of musculoskeletal disorders among adult human immunodeficiency virus-positive patients following anti-retroviral therapy. An institutional-based cross-sectional study was conducted from September 1st to October 1st, 2021 at University of Gondar Comprehensive Specialized Hospital, Gondar, Ethiopia. The data was collected through an interview-administered questionnaire and patient medical record review of 324 participants. Binary logistic regression was used to identify associated risk factors of musculoskeletal disorders. The strength of the association was detected by the adjusted odds ratio and P-value. The annual prevalence of musculoskeletal disorders among participants was 158 (48.5%) with [95% CI: 43%, 54%], opportunistic infection [AOR, 10.43; 95% CI = 2.76-42.25], type of ART medication used, CD4-count [AOR, 0.13; 95% CI 0.03-0.85], and change in anti-retroviral therapy regimen change [AOR, 8.14; 95%CI 2.06-32.09] were significantly associated with musculoskeletal disorders. The prevalence of musculoskeletal disorders was moderate. Recent CD4 count, opportunistic infection, antiretroviral therapy regime at initiation, and anti-retroviral therapy regime change were significantly associated with musculoskeletal disorder. A multidisciplinary approach is required for preventing and treating musculoskeletal disorders among human immunodeficiency virus-positive patients following anti-retroviral therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Musculoskeletal disorders is an inflammatory, degenerative diseases and disorders that cause pain and functional impairments. Musculoskeletal disorders are common and the major global health concern among people with human immunodeficiency virus/acquired immunodeficiency syndrome which causes physical disability. Despite, it is a recognized health problem among human immunodeficiency virus-positive patients, there is a lack of data on musculoskeletal disorders among patients following anti-retroviral therapy in sub-Saharan Africa, particularly Ethiopia. Therefore, the main aim of the study was to assess the prevalence and associated factors of musculoskeletal disorders among adult human immunodeficiency virus-positive patients following anti-retroviral therapy.
METHOD
METHODS
An institutional-based cross-sectional study was conducted from September 1st to October 1st, 2021 at University of Gondar Comprehensive Specialized Hospital, Gondar, Ethiopia. The data was collected through an interview-administered questionnaire and patient medical record review of 324 participants. Binary logistic regression was used to identify associated risk factors of musculoskeletal disorders. The strength of the association was detected by the adjusted odds ratio and P-value.
RESULT
RESULTS
The annual prevalence of musculoskeletal disorders among participants was 158 (48.5%) with [95% CI: 43%, 54%], opportunistic infection [AOR, 10.43; 95% CI = 2.76-42.25], type of ART medication used, CD4-count [AOR, 0.13; 95% CI 0.03-0.85], and change in anti-retroviral therapy regimen change [AOR, 8.14; 95%CI 2.06-32.09] were significantly associated with musculoskeletal disorders.
CONCLUSION
CONCLUSIONS
The prevalence of musculoskeletal disorders was moderate. Recent CD4 count, opportunistic infection, antiretroviral therapy regime at initiation, and anti-retroviral therapy regime change were significantly associated with musculoskeletal disorder. A multidisciplinary approach is required for preventing and treating musculoskeletal disorders among human immunodeficiency virus-positive patients following anti-retroviral therapy.
Identifiants
pubmed: 37596525
doi: 10.1186/s12879-023-08497-1
pii: 10.1186/s12879-023-08497-1
pmc: PMC10436402
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
540Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
J Pain Symptom Manage. 2000 May;19(5):339-47
pubmed: 10869874
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
J Occup Health. 2006 Sep;48(5):366-76
pubmed: 17053303
Pain. 1997 Apr;70(2-3):117-23
pubmed: 9150284
Mayo Clin Proc. 2013 Dec;88(12):1468-74
pubmed: 24290121
J Pain Res. 2017 Oct 13;10:2461-2469
pubmed: 29075137
Pain. 2016 Apr;157(4):931-937
pubmed: 26683238
J Rheumatol. 2001 Apr;28(4):802-4
pubmed: 11327254
Alcohol Alcohol. 2016 Mar;51(2):186-95
pubmed: 26884509
Occup Environ Med. 2012 Apr;69(4):291-5
pubmed: 22006936
Rheumatol Int. 2006 May;26(7):680-2
pubmed: 16133580
Best Pract Res Clin Rheumatol. 2015 Jun;29(3):356-73
pubmed: 26612235
Clin J Pain. 1994 Jun;10(2):156-61
pubmed: 8075469
J Assoc Nurses AIDS Care. 2010 Mar-Apr;21(2):125-33
pubmed: 20116299
Appl Ergon. 1987 Sep;18(3):233-7
pubmed: 15676628
HIV Med. 2007 Jan;8(1):8-16
pubmed: 17305926
PLoS One. 2019 May 13;14(5):e0216787
pubmed: 31083692
Tanzan J Health Res. 2013 Jan;15(1):11-8
pubmed: 26591668
J Pediatr. 2005 Jun;146(6):732-7
pubmed: 15973308
Qual Life Res. 2010 Mar;19(2):157-66
pubmed: 20047029
AIDS Care. 2017 Aug;29(8):1041-1048
pubmed: 28064511
J Int AIDS Soc. 2014 Feb 18;17:18719
pubmed: 24560338
AIDS. 2014 May 15;28(8):1193-202
pubmed: 24556869
J Health Psychol. 2020 Sep;25(10-11):1556-1566
pubmed: 29587530
J Orthop Sports Phys Ther. 2004 Oct;34(10):610-27
pubmed: 15552707
J Acquir Immune Defic Syndr. 2016 Sep 1;73(1):39-46
pubmed: 27028501
Indian J Med Res. 2017 Aug;146(2):175-185
pubmed: 29265018
Indian J Sex Transm Dis AIDS. 2013 Jul;34(2):107-12
pubmed: 24339461
Ann Rheum Dis. 2005 Apr;64(4):606-11
pubmed: 15576417